Irinotecan Tillomed (Irinotecan Hydrochloride Trihydrate)

Irinotecan Tillomed is a cytotoxic agent used in the management of colorectal cancer and related disease stages.

• Metastatic colorectal cancer: provides systemic chemotherapy to reduce tumor burden and extend survival.
• Advanced colorectal cancer: delivers targeted DNA damage to inhibit tumor growth in patients with inoperable disease.

• Irinotecan is a prodrug converted intracellularly to SN‑38, which binds to the DNA‑topoisomerase I complex and prevents relegation of single‑strand breaks. This inhibition leads to accumulation of DNA damage, replication arrest, and ultimately apoptosis of rapidly dividing cancer cells.

Irinotecan therapy is associated with a range of adverse reactions that vary in frequency and severity.

Common Side Effects

• Neutropenia: reduced white blood cell count increasing infection risk.
• Diarrhea: often delayed and may be severe.
• Nausea and vomiting: gastrointestinal upset common after infusion.
• Alopecia: temporary hair loss.
• Fatigue: generalized tiredness during treatment.
• Abdominal pain: cramping or discomfort.

Serious or Rare Side Effects

• Febrile neutropenia: fever with low neutrophils requiring urgent care.
• Severe diarrhea leading to dehydration or electrolyte imbalance.
• Bowel perforation: rare but life‑threatening gastrointestinal rupture.
• Hepatic dysfunction: elevated liver enzymes or jaundice.
• Anaphylactic reactions: rare hypersensitivity to the formulation.
• Hemorrhagic colitis: inflammation with bleeding in the colon.

Prior to initiating Irinotecan therapy, clinicians should assess patient-specific risk factors and monitor relevant clinical parameters.

• Hematologic monitoring: perform baseline and periodic complete blood counts to detect neutropenia.
• Liver function: evaluate hepatic enzymes and bilirubin, adjusting dose in impairment.
• Renal function: assess creatinine clearance, especially in patients with renal insufficiency.
• Pregnancy and lactation: avoid use unless benefits outweigh potential fetal risks; advise against breastfeeding.
• Concomitant myelosuppressives: use caution when combined with other bone‑marrow suppressing agents.

Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Irinotecan may interact with several drug classes, altering its efficacy or toxicity profile.

Major Interactions (Avoid)

• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): markedly reduce SN‑38 exposure.
• Concurrent myelosuppressive chemotherapy: heightens risk of severe neutropenia and thrombocytopenia.
• Cholinesterase inhibitors (e.g., neostigmine): may exacerbate cholinergic syndrome.

Moderate Interactions (Monitor Closely)

• Moderate CYP3A4 inhibitors (e.g., fluconazole, erythromycin): increase SN‑38 levels, requiring dose adjustment.
• Warfarin: potential alteration of INR, necessitating closer coagulation monitoring.
• NSAIDs or aspirin: increase risk of gastrointestinal toxicity and bleeding.
• UGT1A1 inhibitors (e.g., atazanavir): may raise SN‑38 concentrations, especially in patients with reduced enzyme activity.